Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NEXGEL, Inc. (NASDAQ: NXGL) generates news across healthcare, consumer products, and capital markets through developments tied to its ultra-gentle, high-water-content hydrogel technology. The company regularly issues press releases on quarterly financial results, highlighting performance in its contract manufacturing segment and its portfolio of consumer-branded products in health, beauty, and OTC categories.
Investors following NXGL news will see updates on earnings announcements, including revenue trends, gross margin, operating expenses, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Management commentary often discusses demand for branded products, new contract manufacturing agreements, and the impact of partnerships with consumer healthcare companies.
NEXGEL’s news flow also covers strategic and corporate actions. Recent items include the spin-off of select drug delivery application assets into NexGelRx, with NEXGEL retaining a royalty interest, an equity stake, and exclusive hydrogel manufacturing rights. Additional releases have described expanded partnerships, such as the agreement with STADA Arzneimittel AG involving non-dilutive capital to support product launches and marketing efforts, as well as financing transactions like registered direct offerings and concurrent private placements.
Governance and leadership developments are another recurring news theme. NEXGEL has announced board appointments, conference presentations at investor events, and changes in senior finance roles through its press releases and associated SEC filings. Readers of this NXGL news page can review these updates in one place, including information on special meetings of stockholders, strategic advisors to NexGelRx, and other events that shape the company’s direction.
By monitoring the NXGL news feed, market participants can track how NEXGEL’s hydrogel-focused business, partnerships, financings, and governance decisions evolve over time, using official company communications as a primary source.
NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board. Dr. Nelson is a pediatric ophthalmology leader with extensive credentials, including roles at Wills Eye Hospital and Thomas Jefferson University. Dr. Chesen is a seasoned ophthalmologist with over 33 years of experience. Their addition aims to enhance NEXGEL's development of high-water-content hydrogel products for healthcare applications. CEO Adam Levy emphasized that their expertise will significantly aid in advancing the company's innovative hydrogel solutions.
NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) announced that CEO Adam Levy will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022. The presentation is scheduled for September 14, from 9:00 A.M. to 9:30 A.M. Eastern Time. Interested investors can contact their H.C. Wainwright representative or email NEXGEL@kcsa.com for 1x1 meetings. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications, having over two decades of experience in developing these innovative solutions.
NEXGEL reported a 35% year-over-year revenue growth to $561 thousand for Q2 2022, showing a 42% sequential increase. The rise is attributed to successful launches and demand for branded products, such as MEDAGEL Pro Pads. Gross profit improved to $101 thousand, with an 18% margin. However, operating expenses rose to $819 thousand, driven by increased R&D investments and higher SG&A costs. As of June 30, 2022, cash and equivalents stood at $9.7 million, ensuring a solid financial position for ongoing growth initiatives.
NEXGEL (NASDAQ: NXGL) will report its financial and operating results for Q2 2022 on August 10, 2022, after market close. Following the release, a conference call will be held at 4:30 P.M. ET the same day. Interested individuals can join the call via a U.S. toll-free number or international dial-in options, and a webcast will be available on the company’s Investor Relations website. A replay of the call will be accessible until August 17, 2022. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications.
NEXGEL (NASDAQ: NXGL, NXGLW) has launched the MEDAGEL Hydroliner Pro pads designed to protect eyelashes during cosmetic services like extensions and lifts. These pads offer a breathable, flexible, and skin-friendly alternative to traditional options, preventing slippage while being gentle on sensitive skin. They aim to enhance client comfort, allowing for easy removal and replacement during the application process. This product marks NEXGEL's first proprietary business-to-business offering, expanding its innovative hydrogel product line.
NEXGEL (NASDAQ: NXGL, NXGLW) has launched a partnership with Partners for World Health to provide humanitarian support in Ukraine. For every two boxes of SilverSeal® purchased, one will be donated to those in need. In June, 458 boxes were donated, equating to 1,832 healing patches. CEO Adam Levy emphasized the importance of treating skin injuries in crisis zones. The initiative addresses urgent medical needs amid ongoing conflict, aiming to deliver essential supplies through various shipping methods.
NEXGEL, Inc. (NASDAQ: NXGL) reported a 48% year-over-year revenue increase to $396 thousand for Q1 2022, driven by new product launches in its consumer segment. The company introduced two new OTC products: the MEDAGEL ClearComfort Hydrogel Patch and the MEDAGEL Bug Bite Relief Patch. Gross loss improved to $22 thousand from $42 thousand last year, although operating expenses rose to $790 thousand. Cash reserves decreased to $10.5 million due to principal payments on notes payable. The company forecasts continued revenue growth.
NEXGEL, a provider of high-water-content hydrogel products, will announce its first quarter 2022 financial and operating results on May 12, 2022, after market closure. A conference call is scheduled for 4:30 PM/ET on the same day to discuss these results. The call can be accessed via toll-free numbers and will be webcast live, with an archive available for 90 days. The company specializes in skin-friendly hydrogels, developing over 200 combinations using natural ingredients for long-term wear with minimal irritation.
NEXGEL, a provider of high-water-content hydrogel products, announces CEO Adam Levy's participation at the Planet MicroCap Showcase 2022 from May 3-5, 2022, in Las Vegas. Levy's presentation is scheduled for May 4, 2022, at 10:30 AM PT, with a webcast accessible for those unable to attend. Interested investors can book 1x1 meetings during the conference. NEXGEL specializes in gentle skin patches utilizing over 200 formulations and has been developing hydrogels for over 20 years.
NexGel, Inc. (NASDAQ: NXGL), a leader in ultra-gentle hydrogel products, will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. CEO Adam Levy's presentation will be available on-demand at the conference's start. Attendees can register to join here. With over two decades of experience, NexGel specializes in high-water-content hydrogels for healthcare and consumer use.